#1 Clinical Trials Search in Europe

Gskvx000000009151

This article discusses clinical trials investigating the use of GSKVX000000009151, a novel therapeutic vaccine, for the treatment of chronic hepatitis B (CHB). The trials aim to evaluate the safety, efficacy, and immune response of this vaccine in combination with other treatments in patients with CHB who are already on nucleos(t)ide analogue (NA) therapy.

Table of Contents

Overview of GSKVX000000009151

GSKVX000000009151 is an innovative therapeutic vaccine being developed by GlaxoSmithKline Biologicals S.A. for the treatment of chronic hepatitis B (CHB)[1]. This vaccine is part of a new generation of treatments aimed at improving outcomes for patients with chronic hepatitis B who are currently on nucleos(t)ide analogue (NA) therapy[2].

Mechanism of Action

GSKVX000000009151 is designed as a targeted immunotherapy for chronic hepatitis B. It works by stimulating the immune system to mount a more effective response against the hepatitis B virus (HBV)[1]. The vaccine contains specific HBV components that help trigger both humoral (antibody-mediated) and cellular immune responses, particularly targeting the hepatitis B core (HBc) and surface (HBs) antigens[2].

Indications and Target Population

This therapeutic vaccine is being studied for use in adult patients (aged 18-65) with chronic hepatitis B who are currently on nucleos(t)ide analogue therapy and have achieved viral suppression[1]. It may be suitable for both HBeAg-positive and HBeAg-negative patients[2]. The goal is to improve treatment outcomes in patients who have achieved viral suppression but still have detectable levels of hepatitis B surface antigen (HBsAg).

Administration and Dosage

GSKVX000000009151 is administered as an intramuscular injection[1]. The exact dosing schedule is still being investigated in clinical trials, but it may involve multiple doses given over several weeks or months. In some studies, it is being tested in combination with other treatments, such as antiviral medications or other experimental therapies[2].

Efficacy and Treatment Goals

The primary goals of treatment with GSKVX000000009151 include:

  • Reducing levels of hepatitis B surface antigen (HBsAg) in the blood
  • Achieving HBsAg loss, which is considered a functional cure for chronic hepatitis B
  • Stimulating a robust immune response against HBV
  • Maintaining long-term viral suppression after stopping nucleos(t)ide analogue therapy

Clinical trials are measuring efficacy by looking at the percentage of patients who achieve a significant decrease in HBsAg levels or complete HBsAg loss[2]. Researchers are also monitoring immune responses, including the production of anti-HBs antibodies and the activation of HBV-specific T cells[2].

Safety Profile

As GSKVX000000009151 is still in clinical trials, its full safety profile is not yet established. However, researchers are closely monitoring for any adverse events, with particular attention to:

  • Injection site reactions (such as redness, pain, and swelling)
  • Systemic reactions (like fever or fatigue)
  • Any serious adverse events or immune-mediated side effects

The safety of the vaccine is being evaluated in various patient populations, including those with different levels of liver function and HBV viral load[1][2].

Ongoing Research and Future Prospects

GSKVX000000009151 is currently being studied in Phase I/II clinical trials[1]. These studies are evaluating its safety, efficacy, and optimal dosing regimens. Some key aspects of ongoing research include:

  • Testing the vaccine in combination with other treatments, such as antiviral medications or experimental therapies like antisense oligonucleotides
  • Investigating its potential in different subgroups of chronic hepatitis B patients
  • Assessing long-term outcomes and the durability of treatment responses

If successful, GSKVX000000009151 could represent a significant advance in the treatment of chronic hepatitis B, potentially offering a path to functional cure for some patients[2]. However, it’s important to note that more research is needed to fully understand its efficacy and safety profile before it can be considered for widespread use.

Aspect Details
Study Type Phase I/II and Phase II clinical trials
Intervention GSKVX000000009151 (therapeutic vaccine) in combination with other treatments
Target Population Adults with chronic hepatitis B on stable nucleos(t)ide analogue therapy
Primary Objectives Assess safety, efficacy, and immune response of the treatment regimens
Key Endpoints Reduction in HBsAg levels, HBsAg loss, anti-HBs seroconversion, T-cell responses
Safety Monitoring Adverse events, serious adverse events, laboratory abnormalities
Study Duration Variable, with long-term follow-up for safety and efficacy

FAQ

  • What is GSKVX000000009151? GSKVX000000009151 is an investigational therapeutic vaccine being studied for the treatment of chronic hepatitis B. It is designed to stimulate the immune system to fight against the hepatitis B virus.
  • Who is eligible to participate in these clinical trials? Eligible participants are adults aged 18-65 with chronic hepatitis B who are stable on nucleos(t)ide analogue therapy. They must have controlled viral levels and meet specific criteria for liver function and overall health.
  • How is GSKVX000000009151 administered? GSKVX000000009151 is administered as an intramuscular injection. The exact dosing schedule varies depending on the specific trial protocol.
  • What are the main goals of these clinical trials? The main goals are to assess the safety, efficacy, and immune response of GSKVX000000009151 when used in combination with other treatments for chronic hepatitis B. Researchers are looking at factors such as reduction in hepatitis B surface antigen (HBsAg) levels and development of an immune response against the virus.
  • What are the potential benefits and risks of participating? Potential benefits include improved control of hepatitis B infection and possible reduction in viral markers. Risks may include injection site reactions, immune-related side effects, and other adverse events. All participants are closely monitored for safety throughout the trials.

Ongoing Clinical Trials on Gskvx000000009151

  • Study on the Safety and Effectiveness of GSKVX000000008866 and GSKVX000000009151 in Adults with Chronic Hepatitis B on Nucleotide Analogue Therapy

    Not recruiting

    1
    Investigated drugs:
    Belgium Germany Spain

  • Study on Safety and Efficacy of Bepirovirsen and Drug Combination for Chronic Hepatitis B in Patients on Nucleos(t)ide Analogue Therapy

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria France Germany Italy Poland +2

Glossary

  • Chronic Hepatitis B (CHB): A long-lasting liver infection caused by the hepatitis B virus that can lead to serious liver damage if left untreated.
  • Nucleos(t)ide analogue (NA) therapy: A type of antiviral medication used to suppress hepatitis B virus replication in patients with chronic infection.
  • HBsAg (Hepatitis B surface antigen): A protein on the surface of the hepatitis B virus that is detectable in the blood and indicates ongoing infection.
  • Therapeutic vaccine: A vaccine designed to treat an existing disease by stimulating the immune system, rather than preventing infection.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, or causes significant disability.
  • Efficacy: The ability of a treatment to produce the desired beneficial effect under ideal circumstances.
  • Randomized controlled trial: A type of scientific experiment where participants are randomly assigned to different treatment groups to compare outcomes.
  • Sustained Virologic Response (SVR): In hepatitis B treatment, this refers to a sustained reduction or elimination of detectable virus in the blood after completing therapy.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-gskvx000000008866-and-gskvx000000009151-in-adults-with-chronic-hepatitis-b-on-nucleotide-analogue-therapy/
  2. http://clinicaltrials.eu/trial/study-on-safety-and-efficacy-of-bepirovirsen-and-drug-combination-for-chronic-hepatitis-b-in-patients-on-nucleostide-analogue-therapy/